Why the future of healthcare innovation requires CDMOs that go beyond production and become true collaborators.

More Than a Capsule

Every capsule we deliver carries more than a formulation, it carries a promise of trust, safety, and care. For Softgel Healthcare, this statement reflects a fundamental shift in how CDMOs should operate. In an industry where timelines are critical and compliance is non-negotiable, being just a contract manufacturer is no longer enough. The future belongs to those who become partners in possibility.

Part of Madras Group, Committed to Healthcare

Operating from its global headquarters in Chennai, India, Softgel Healthcare draws strength from being part of the Madras Pharma Group, a healthcare leader with a 40+ year history, eight facilities across India, and more than 3,000 employees dedicated to advancing pharmaceuticals and nutraceuticals worldwide.

This backing provides Softgel with the stability of a trusted legacy player, combined with the agility to focus on global healthcare growth and innovation in softgel formats.

Beyond the CDMO Label

Softgel Healthcare has built its business model on more than production. In addition to its core CDMO services, the company offers contract research (CRO), co-development partnerships, and out-licensing of in-house developments.

This integrated approach empowers pharma and nutraceutical brands to move faster and more confidently from concept to market. It transforms the CDMO relationship from transactional to collaborative, positioning Softgel as a bridge between science, compliance, and patient impact.

Co-Creation as a Driver of Innovation

At the heart of this philosophy is co-creation. Softgel’s dedicated teams of 7+ formulation scientists, 25+ analytical scientists, and 15+ regulatory experts support projects from early-stage trials through to commercial launch.

Capabilities include:

• High-potent softgels and specialized lines with containment strategies aligned to global guidelines.
• Advanced formats such as enteric-coated, liposomal, chewable, and pearlescent capsules.
• Liquid-filled hardgels that expand formulation possibilities.
• Proven expertise in tablet-to-softgel conversions and 505 (b)(2) reformulation projects that enhance bioavailability and lifecycle management.

With the capacity to manufacture 2 billion capsules annually, including up to 300 million high-potent softgels, Softgel ensures that innovation can scale without compromise.

Trust, Transparency, and Integrity in Action

For Softgel, partnership is not a claim but a system. The company is audited 40–50 times a year by global pharma leaders, ensuring rigorous compliance. A dedicated Tech Transfer and Project Management team of more than 40 professionals ensures smooth scale-up, meticulous documentation, and transparent communication throughout every stage of product development.

This commitment has made Softgel the trusted choice for 100+ global clients, not just because of capacity, but because of its culture of reliability and integrity.

Building the Future Together

The healthcare challenges of today require more than speed and scale. They require CDMOs willing to sit beside their clients as collaborators, problem-solvers, and enablers of new possibilities.

Softgel Healthcare’s promise is simple yet profound: to be more than a manufacturer, to be a partner in possibility.

For more information, visit softgelhealthcare.com and follow Softgel Healthcare on LinkedIn.For more information, visit softgelhealthcare.com and follow Softgel Healthcare on LinkedIn.